Amyloid-β misfolding as a plasma biomarker indicates risk for future clinical Alzheimer’s disease in individuals with subjective cognitive decline

Amyloid-β misfolding as a plasma biomarker indicates risk for future clinical Alzheimer’s disease in individuals with subjective cognitive decline

Abstract Background We evaluated Aβ misfolding in combination with Aβ42/40 ratio as a prognostic tool for future clinical progression to mild cognitive impairment (MCI) or dementia due to Alzheimer’s disease (AD) in individuals with subjective cognitive decline (SCD). Methods Baseline plasma samples...

Full description

Bibliographic Details
Main Authors: Julia Stockmann, Inge M. W. Verberk, Nina Timmesfeld, Robin Denz, Brian Budde, Julia Lange-Leifhelm, Philip Scheltens, Wiesje M. van der Flier, Andreas Nabers, Charlotte E. Teunissen, Klaus Gerwert
Format: Article
Language:English
Published: BMC 2020-12-01
Series:Alzheimer’s Research & Therapy
Subjects:
Alzheimer’s disease
Amyloid beta (Aβ)
Blood plasma
Risk stratification
Structure biomarker
Online Access:https://doi.org/10.1186/s13195-020-00738-8

Internet

https://doi.org/10.1186/s13195-020-00738-8

Similar Items